Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Drug checking services at music festivals and events in a Canadian setting.

McCrae K, Tobias S, Tupper K, Arredondo J, Henry B, Mema S, Wood E, Ti L.

Drug Alcohol Depend. 2019 Dec 1;205:107589. doi: 10.1016/j.drugalcdep.2019.107589. Epub 2019 Oct 4.

PMID:
31605958
2.

Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada.

Argento E, Capler R, Thomas G, Lucas P, Tupper KW.

Drug Alcohol Rev. 2019 Nov;38(7):781-789. doi: 10.1111/dar.12985. Epub 2019 Sep 5.

PMID:
31489731
3.

"We don't got that kind of time, man. We're trying to get high!": Exploring potential use of drug checking technologies among structurally vulnerable people who use drugs.

Bardwell G, Boyd J, Tupper KW, Kerr T.

Int J Drug Policy. 2019 Sep;71:125-132. doi: 10.1016/j.drugpo.2019.06.018. Epub 2019 Jul 20.

PMID:
31336258
4.

The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis.

Argento E, Tupper KW, Socias ME.

Int J Drug Policy. 2019 Apr;66:80-81. doi: 10.1016/j.drugpo.2018.11.006. Epub 2019 Feb 7.

PMID:
30743091
5.

Principles, practice, and policy vacuums: Policy actor views on provincial/territorial harm reduction policy in Canada.

Hyshka E, Anderson-Baron J, Pugh A, Belle-Isle L, Hathaway A, Pauly B, Strike C, Asbridge M, Dell C, McBride K, Tupper K, Wild TC.

Int J Drug Policy. 2019 Sep;71:142-149. doi: 10.1016/j.drugpo.2018.12.014. Epub 2019 Jan 30.

PMID:
30711412
6.

An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders.

Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A.

Eat Weight Disord. 2018 Nov 24. doi: 10.1007/s40519-018-0619-6. [Epub ahead of print]

PMID:
30474794
7.

3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) use and transitions to injection drug use among street-involved youth.

Lake S, Gaddis A, Tupper KW, Nosova E, DeBeck K.

Subst Abus. 2019;40(3):350-355. doi: 10.1080/08897077.2018.1528493. Epub 2018 Nov 20.

PMID:
30457939
8.

Drug checking as a potential strategic overdose response in the fentanyl era.

Laing MK, Tupper KW, Fairbairn N.

Int J Drug Policy. 2018 Dec;62:59-66. doi: 10.1016/j.drugpo.2018.10.001. Epub 2018 Oct 22.

PMID:
30359874
9.

Drug checking at an electronic dance music festival during the public health overdose emergency in British Columbia.

Mema SC, Sage C, Xu Y, Tupper KW, Ziemianowicz D, McCrae K, Leigh M, Munn MB, Taylor D, Corneil T.

Can J Public Health. 2018 Dec;109(5-6):740-744. doi: 10.17269/s41997-018-0126-6. Epub 2018 Sep 24.

PMID:
30251119
10.

Regular MDMA use is associated with decreased risk of drug injection among street-involved youth who use illicit drugs.

Gaddis A, Lake S, Tupper K, Nosova E, Blommaert K, Wood E, DeBeck K.

Drug Alcohol Depend. 2018 Nov 1;192:112-117. doi: 10.1016/j.drugalcdep.2018.07.035. Epub 2018 Sep 12.

11.

Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting.

Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E.

Drug Alcohol Depend. 2018 Sep 1;190:242-245. doi: 10.1016/j.drugalcdep.2018.06.020. Epub 2018 Jul 24.

PMID:
30064061
12.

Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting.

Argento E, Strathdee SA, Tupper K, Braschel M, Wood E, Shannon K.

BMJ Open. 2017 Sep 21;7(9):e016025. doi: 10.1136/bmjopen-2017-016025.

13.

Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders.

Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW.

J Psychoactive Drugs. 2017 Nov-Dec;49(5):427-435. doi: 10.1080/02791072.2017.1361559. Epub 2017 Sep 12.

PMID:
28895501
14.

Canadian harm reduction policies: A comparative content analysis of provincial and territorial documents, 2000-2015.

Wild TC, Pauly B, Belle-Isle L, Cavalieri W, Elliott R, Strike C, Tupper K, Hathaway A, Dell C, MacPherson D, Sinclair C, Karekezi K, Tan B, Hyshka E.

Int J Drug Policy. 2017 Jul;45:9-17. doi: 10.1016/j.drugpo.2017.03.014. Epub 2017 Apr 25. Review.

PMID:
28454045
15.

A Public-Health-Based Vision for the Management and Regulation of Psychedelics.

Haden M, Emerson B, Tupper KW.

J Psychoactive Drugs. 2016 Sep-Oct;48(4):243-52. doi: 10.1080/02791072.2016.1202459. Epub 2016 Jul 18.

PMID:
27430375
16.

Psychedelic medicine: a re-emerging therapeutic paradigm.

Tupper KW, Wood E, Yensen R, Johnson MW.

CMAJ. 2015 Oct 6;187(14):1054-1059. doi: 10.1503/cmaj.141124. Epub 2015 Sep 8. Review. No abstract available.

17.
18.

Delayed administration of bone marrow mesenchymal stem cell conditioned medium significantly improves outcome after retinal ischemia in rats.

Dreixler JC, Poston JN, Balyasnikova I, Shaikh AR, Tupper KY, Conway S, Boddapati V, Marcet MM, Lesniak MS, Roth S.

Invest Ophthalmol Vis Sci. 2014 Apr 3;55(6):3785-96. doi: 10.1167/iovs.13-11683.

19.

Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada.

Thomas G, Lucas P, Capler NR, Tupper KW, Martin G.

Curr Drug Abuse Rev. 2013 Mar;6(1):30-42.

PMID:
23627784
20.

Statement on ayahuasca.

Anderson BT, Labate BC, Meyer M, Tupper KW, Barbosa PC, Grob CS, Dawson A, McKenna D.

Int J Drug Policy. 2012 May;23(3):173-5. doi: 10.1016/j.drugpo.2012.02.007. Epub 2012 Mar 27. No abstract available.

PMID:
22459485
21.

Ammonia-induced brain swelling and neurotoxicity in an organotypic slice model.

Back A, Tupper KY, Bai T, Chiranand P, Goldenberg FD, Frank JI, Brorson JR.

Neurol Res. 2011 Dec;33(10):1100-8. doi: 10.1179/1743132811Y.0000000046.

22.

Delayed post-ischemic conditioning significantly improves the outcome after retinal ischemia.

Dreixler JC, Poston JN, Shaikh AR, Alexander M, Tupper KY, Marcet MM, Bernaudin M, Roth S.

Exp Eye Res. 2011 Jun;92(6):521-7. doi: 10.1016/j.exer.2011.03.015. Epub 2011 Apr 9.

23.

The globalization of ayahuasca: harm reduction or benefit maximization?

Tupper KW.

Int J Drug Policy. 2008 Aug;19(4):297-303. doi: 10.1016/j.drugpo.2006.11.001. Epub 2006 Dec 4.

PMID:
18638702
24.

A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation.

Callaway JC, Grob CS, McKenna DJ, Nichols DE, Shulgin A, Tupper KW.

J Anal Toxicol. 2006 Jul-Aug;30(6):406-7; author reply 407. No abstract available.

PMID:
16872575
25.

ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.

Lombardo F, Shalaeva MY, Tupper KA, Gao F.

J Med Chem. 2001 Jul 19;44(15):2490-7.

PMID:
11448232
26.

ElogPoct: a tool for lipophilicity determination in drug discovery.

Lombardo F, Shalaeva MY, Tupper KA, Gao F, Abraham MH.

J Med Chem. 2000 Jul 27;43(15):2922-8.

PMID:
10956200

Supplemental Content

Loading ...
Support Center